Legacy Capital Group California has bought 2,440 shares in Vertex Pharmaceuticals Incorporated. A wide range of institutional investors have boosted their positions in Vertex, including Neo Ivy Capital Management and 111 Capital. Notably, Dimensional Fund Advisors and Victory Capital Management Inc. purchased significant numbers of shares, further demonstrating strong investor attraction towards the company.
Vertex's revenue hit $12 billion last year, leading analysts to point to a potential $815 stock price. Its Q4 earnings reportedly missed estimates, but it still posted strong returns, compelling investors to consider its long-term growth potential and valuation, especially after its Q4 beat and growing confidence in Povetacicept. A non-opioid pain drug developed by the company has been making waves in the plastic surgery sector, helping patients avoid opioids post-surgery.
This pharmaceutical giant continues to make strides with its renal pipeline, described as a significant growth driver by Barclays. Vertex's progress was also evident at the BofA Global Healthcare Conference, where the company highlighted its pipeline's advancement.
Vertex Pharmaceuticals VRTX News Analytics from Mon, 02 Jun 2025 15:34:51 GMT to Sat, 07 Mar 2026 12:04:54 GMT - Rating 7 - Innovation -1 - Information 6 - Rumor -3
